MannKind reports positive Afrezza® clinical data from STAT and AFFINITY studies
MannKind announced new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections). The dual primary endpoints were assessment of glucose time-in-range and PPG excursions. June 23, 2018